Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03871816 · ClinicalTrials.gov registry record
A Study to Determine Frequency of DNA-repair Defects in Men With Metastatic Prostate Cancer
A clinical trial, sponsored by Janssen Research & Development.
- Completed
- Registry status
- 14,532
- Enrollment target
NCT03871816: Completed study, sponsored by Janssen Research & Development.
NCT03871816 is a clinical trial that has completed, run by Janssen Research & Development. The registered enrollment target is 14,532 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03871816 has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- 14,532 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the prevalence of 4 or more DNA-repair gene defects in a population of men with metastatic Prostate Cancer (PC) and to use the reported DNA-repair gene defects to assess biomarker eligibility for niraparib interventional studies.
Primary Outcome
Percentage of participants with 4 or more Deoxyribonucleic acid (DNA)-repair gene defects with metastatic Prostate Cancer (PC) as an estimate for prevalence will be assessed. A saliva, blood, and/or archival tumor tissue sample will be collected for genomic testing to confirm DNA-repair gene defect (DRD) status.
Interventions
- OTHER Saliva, Blood, or and/or Archival Tumor Tissue Collection and Analysis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14,532 participants |
| Start Date | 2019-04-22 |
| Est. Completion | 2022-11-22 |
What the finished NCT03871816 record still lists
NCT03871816 is an observational study that tracks outcomes without assigning an intervention. Its 14,532 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 1 intervention - of which Saliva, Blood, or and/or Archival Tumor Tissue Collection and Analysis is the first listed.
NCT03871816 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03871816 about?
NCT03871816 is a clinical study titled "A Study to Determine Frequency of DNA-repair Defects in Men With Metastatic Prostate Cancer". The purpose of this study is to evaluate the prevalence of 4 or more DNA-repair gene defects in a population of men with metastatic Prostate Cancer (PC) and to use the reported DNA-repair gene defects to assess biomarker eligibility for niraparib interventional studies.
What is the current status of trial NCT03871816?
This trial is currently completed. The enrollment target is 14,532 participants. The study started on 2019-04-22. Estimated completion is 2022-11-22.
What interventions are being tested in trial NCT03871816?
The interventions under investigation include: Saliva, Blood, or and/or Archival Tumor Tissue Collection and Analysis (OTHER).
Who is sponsoring clinical trial NCT03871816?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05359016 · 14,600 participants · NA
Evaluating Innovative Technologies and Approaches to Addressing Cervical Cancer in Gaza and Maputo Cidade Provinces in Mozambique
- NCT05591066 · 14,400 participants · NA
The Patient and Family Centered I-PASS LISTEN Study: Language, Inclusion, Safety, and Teamwork for Equity Now
- NCT06849869 · 14,820 participants · NA
Collaborative Care Model for Perinatal Wellness Support Services - Population-Level Equity-Centered Systems Change
- NCT00857922 · 15,000 participants
Neurosciences Research Repository
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI